Implantable Sensor Enters First Clinical Trial

Senseonics Holdings announces that the extended life Eversense XL sensor that lasts up to 180 days has been implanted in the first US study participant as part of the clinical trial for pre-market application submission to the Food and Drug Administration. The study is intended to evaluate the safety and efficacy of the Eversense CGM system in people with diabetes over a 180-day period.


Approximately 180 study participants at up to 15 locations across the United States are planned to enroll in the study. The Eversense XL sensor previously received the CE Mark and is currently marketed to patients across the European Union.

Free Newsletter

Like this article? Subscribe to FierceSensors!

The sensors industry is constantly changing as innovation runs the market’s trends. FierceSensors subscribers rely on our suite of newsletters as their must-read source for the latest news, developments and analysis impacting their world. Register today to get sensors news and updates delivered right to your inbox.


Senseonics also announced that the company has completed its submission of PMA supplements to the FDA to secure an insulin dosing claim and to remove the contraindication related to the Magnetic Resonance Imaging (MRI) exposure on the 90-day system which is currently available in the United States.


For more information, visit Senseonics.


Suggested Articles

Silicon Carbide seen as important for electric vehicles, industrial uses

Nvidia GPUs also behind new Azure NDv2 cloud process

Intel also launched oneAPI initiative to reduce complexity for developers